Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

doi:10.3324/haematol.2013.096537

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Haematologica - 1 Sept 2014

Hanfstein Benjamin, Lauseker Michael, Hehlmann Rüdiger, Saussele Susanne, Erben Philipp, Dietz Christian, Fabarius Alice, Proetel Ulrike, Schnittger Susanne, Haferlach Claudia, Krause Stefan W, Schubert Jörg, Einsele Hermann, Hänel Mathias, Dengler Jolanta, Falge Christiane, Kanz Lothar, Neubauer Andreas, Kneba Michael, Stegelmann Frank, Pfreundschuh Michael, Waller Cornelius F, Spiekermann Karsten, Baerlocher Gabriela M, Pfirrmann Markus, Hasford Joerg, Hofmann Wolf-Karsten, Hochhaus Andreas, Müller Martin C

Abstract excerpt

The vast majority of chronic myeloid leukemia patients express a BCR-ABL1 fusion gene mRNA encoding a 210 kDa tyrosine kinase which promotes leukemic transformation. A possible differential impact of the corresponding BCR-ABL1 transcript variants e13a2 ("b2a2") and e14a2 ("b3a2") on disease phenotype and outcome is still a subject of debate. A total of 1105 newly diagnosed imatinib-treated patients were analyzed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Blood Platelets

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Leukocytes

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 24837466
DOI: 10.3324/haematol.2013.096537
PMCID: PMC4562532

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.PMID 24837466Read ↗

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of KashmirSemantic proximity Read ↗

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcriptSemantic proximity Read ↗

A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD)Semantic proximity Read ↗

A Rare e14a3 (b3a3) BCR-ABL Fusion Transcript in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.Semantic proximity Read ↗

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.Semantic proximity Read ↗

Prevalence and outcomes of uncommon BCR ‐ ABL 1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centreSemantic proximity Read ↗

[Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].Semantic proximity Read ↗

A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes.Semantic proximity Read ↗

Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Treatment and molecular monitoring update in chronic myeloid leukemia management.Semantic proximity Read ↗

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.